Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study ...(of products that address serious disease...),Health

Date:8/19/2007

of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R) approved for oral administration for treatment of antibiotic- associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information, please download the package insert at http://www.viropharma.com/docs/Vancocin_pi_2007.htm). ViroPharma currently focuses its drug development activities in viral diseases including cytomegalovirus (CMV) and hepatitis C (HCV). For more information on ViroPharma, visit the Company's website at http://www.viropharma.com.

Certain statements in this press release contain forward-looking statements that involve a number of risks and uncertainties including those relating to the future of the Company's HCV clinical development program and the Company's hope of advancing HCV-796 as a potential therapeutic agent in the future. Our actual results could differ materially from those results expressed in, or implied by, these forward-looking statements. Conducting clinical trials for investigational pharmaceutical products is subject to risks and uncertainties. The antiviral data that is described in this press release is preliminary and additional safety and antiviral data will become available in the future. Full analysis of the existing and future data may not support any or all of the statements in this press release. There can be no assurance that ViroPharma will conduct additional HCV studies in the future. The FDA or other regulatory authorities may either prohibit any future studies with HCV-796 or alternatively may require additional or unanticipated studies or clinical trial outcomes before granting regulatory approval. The can be no guarantee that
'/>"/>

SOURCE ViroPharma Incorporated Copyright©2007 PR Newswire.

0 GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. New Information on the Potential of Plasmin Shared at ISTH Congress
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
5. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
6. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
7. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
8. Expert Opinion Highlights Avigens AV411 as Potential New Therapeutic for Neuropathic Pain and Opioid Withdrawal
9. New Study Shows That telmisartan has Greater Renoprotective Potential Thanlosartan in Hypertensive Patients With Type 2 Diabetes
10. Pluristems PLX Cells Demonstrate Potential to Treat Parkinsons Disease
11. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood